Free tool
FAERS Monitor: Miostat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 016968 or its brand name (Miostat, Carbachol). Reports on generic versions are filed under their own applications.
Reports
167
Serious
132
79% of reports
Hospitalization
54
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use35
- abdominal discomfort33
- drug abuse32
- lower respiratory tract infection32
- product dose omission issue32
- amyloid arthropathy31
- arthropathy31
- intentional product misuse31
- obesity31
- pulmonary pain31
- rash31
- drug dependence30
- overdose30
- knee arthroplasty28
- endophthalmitis24
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 6 |
| 2006 | 14 |
| 2007 | 10 |
| 2008 | 1 |
| 2009 | 8 |
| 2010 | 13 |
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 15 |
| 2022 | 11 |
| 2023 | 1 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,992 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amyloid arthropathySignal | 31 | 100210.9 | 64117.1 | 1,675,375 |
| pulmonary painSignal | 31 | 1351.9 | 981.9 | 40,082 |
| endophthalmitisSignal | 24 | 505.9 | 349.1 | 11,551 |
| obesitySignal | 31 | 245.6 | 178.7 | 7,300 |
| knee arthroplastySignal | 28 | 167.7 | 119.6 | 4,474 |
| lower respiratory tract infectionSignal | 32 | 88.7 | 64.9 | 2,691 |
| arthropathySignal | 31 | 70.3 | 51.1 | 2,053 |
| drug abuseSignal | 32 | 48.4 | 35.5 | 1,445 |
| intentional product misuseSignal | 31 | 44.6 | 32.5 | 1,283 |
| abdominal discomfortSignal | 33 | 24.8 | 18.3 | 735 |
| drug dependenceSignal | 30 | 23.5 | 17.0 | 629 |
| overdoseSignal | 30 | 17.5 | 12.7 | 455 |
| product dose omission issueSignal | 32 | 13.7 | 10.0 | 369 |
| rashSignal | 31 | 9.0 | 6.5 | 216 |
| off label useSignal | 35 | 5.0 | 3.7 | 114 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.